Anson Group Discloses 9.3% Stake in NRX Pharmaceuticals (NRXP)
Anson Funds and affiliated managers disclose a 9.3% stake in NRX Pharmaceuticals (NRXP), holding 1,604,975 shares.
Rhea-AI Filing Summary
Anson Funds and affiliated managers disclose a 9.3% stake in NRX Pharmaceuticals (NRXP), holding 1,604,975 shares. The filing states these shares are held by Anson Funds Management LP and related entities and individuals, including Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo and Moez Kassam. The percentage is calculated using 17,289,192 shares outstanding as reported in NRX Pharmaceuticals' May 15, 2025 quarterly report. The filing indicates shared voting and dispositive power over the 1,604,975 shares and certifies the position was acquired in the ordinary course of business and not for the purpose of changing control.
Positive
- None.
Negative
- None.
Insights
TL;DR: Anson group reports a significant 9.3% passive stake in NRXP, disclosing shared voting and dispositive power.
The Schedule 13G/A shows the Anson group collectively holds 1,604,975 shares, representing 9.3% of NRXP based on 17,289,192 outstanding shares. Classification entries indicate roles across investment adviser, parent/holding and control-person categories depending on entity. The filing follows the passive-investor disclosure path by certifying ordinary-course acquisition and no intent to influence control. For investors, a passive 9.3% holder is material because it crosses the 5% reporting threshold, but the statement explicitly denies activist intent; therefore this is a transparency event rather than an announced strategic change.
TL;DR: The filing documents shared authority among affiliated managers, which matters for governance transparency.
All reporting persons list 0 sole voting or dispositive power and 1,604,975 shared voting and dispositive power, indicating joint control among the named entities and individuals. The disclosure identifies the regulatory status (Canadian investment advisor for some filers) and includes certifications about acquisition purpose and regulatory comparability. This clarifies voting structures and ownership attribution but does not indicate any changes to board composition or corporate control.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was the stake reported as acquired to influence control of NRX Pharmaceuticals?
Which entities and individuals are listed as reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.